When does a drug typically receive FDA approval in the drug development process?

When does a drug typically receive FDA approval in the drug development process?

• A. After phase 3 studies are completed and an NDA is submitted to the FDA.
• B. After phase 1 studies are completed.
• C. After phase 2 studies are completed.
• D. After NDA submission but before phase 3.

Answer: (A)

The key idea is that FDA approval requires a complete, robust data package from late-stage trials submitted in an NDA for regulatory review. Phase 3 trials provide the large-scale confirmation of efficacy and safety needed to judge the benefit–risk balance in a broad population. Only after these Phase 3 results are gathered and the sponsor files the NDA can the FDA start its formal review and decide on approval. Early-phase studies (Phase 1 or Phase 2) don’t provide enough evidence for marketing approval, and approval can’t occur before an NDA is submitted for FDA review.

The key idea is that FDA approval requires a complete, robust data package from late-stage trials submitted in an NDA for regulatory review. Phase 3 trials provide the large-scale confirmation of efficacy and safety needed to judge the benefit–risk balance in a broad population. Only after these Phase 3 results are gathered and the sponsor files the NDA can the FDA start its formal review and decide on approval. Early-phase studies (Phase 1 or Phase 2) don’t provide enough evidence for marketing approval, and approval can’t occur before an NDA is submitted for FDA review.